Phase 1/2a Clinical Trial of BI-1206, a Monoclonal Antibody to Fcγriib, in Combination with Rituximab in Subjects with Indolent B-Cell Non-Hodgkin Lymphoma That Has Relapsed or Is Refractory to Rituximab
Blood(2021)
摘要
Introduction
更多查看译文
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要